NCT07002905

A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities

A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets and ASC30 Tablets A1 in Participants With Obesity or Overweight With Weight-Related Comorbidities

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 125 (actual)
• Sponsor: Ascletis Pharma (China) Co., Limited · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This randomized, double-blind, placebo-controlled phase IIa study is designed to evaluate the efficacy, safety, and tolerability of ASC30 Tablets and ASC30 Tablets A1.

Conditions

• Chronic Weight Management

Interventions

Type	Name	Description
DRUG	ASC30 tablets or ASC30 tablets A1 or placebo	Drug: ASC30 tablets or ASC30 tablets A1 administered orally daily Drug: Placebo administered orally daily

Timeline

• Start date: 2025-07-03
• Primary completion: 2025-12-08
• Completion: 2025-12-08
• First posted: 2025-06-04
• Last updated: 2025-12-15

Locations

6 sites across 1 country: United States

Regulatory

• FDA-regulated drug study